share_log

4: Statement of changes in beneficial ownership of securities-Officer WORLAND STEPHEN T

4: Statement of changes in beneficial ownership of securities-Officer WORLAND STEPHEN T

4：持股变动声明-高管 WORLAND STEPHEN T
美股sec公告 ·  05/17 16:03
Moomoo AI 已提取核心信息
On May 15, 2024, Stephen T. Worland, the Chief Executive Officer of eFFECTOR Therapeutics, Inc. (EFTR), completed a purchase of 1,806 shares of common stock at a price of $1.683 per share. Following this transaction, Worland's direct holdings in the company increased to 12,494 shares. The transaction is classified as a grant, award, or other acquisition, according to the transaction code description. In addition to his direct holdings, Worland also has an indirect beneficial ownership of 22,493 shares through a trust.
On May 15, 2024, Stephen T. Worland, the Chief Executive Officer of eFFECTOR Therapeutics, Inc. (EFTR), completed a purchase of 1,806 shares of common stock at a price of $1.683 per share. Following this transaction, Worland's direct holdings in the company increased to 12,494 shares. The transaction is classified as a grant, award, or other acquisition, according to the transaction code description. In addition to his direct holdings, Worland also has an indirect beneficial ownership of 22,493 shares through a trust.
2024年5月15日，Effector Therapeutics, Inc.（EFTR）首席执行官斯蒂芬·沃兰德以每股1.683美元的价格完成了对1,806股普通股的收购。在这笔交易之后，Worland在该公司的直接持股量增加到12,494股。根据交易代码描述，该交易被归类为赠款、奖励或其他收购。除了直接持有外，沃兰德还通过信托拥有22,493股股票的间接实益所有权。
2024年5月15日，Effector Therapeutics, Inc.（EFTR）首席执行官斯蒂芬·沃兰德以每股1.683美元的价格完成了对1,806股普通股的收购。在这笔交易之后，Worland在该公司的直接持股量增加到12,494股。根据交易代码描述，该交易被归类为赠款、奖励或其他收购。除了直接持有外，沃兰德还通过信托拥有22,493股股票的间接实益所有权。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息